HRAS and head and neck squamous cell carcinoma: Importantly, we also first identified that HNSCC patient tumors with high allele frequencies of MAPK-activating mutations, such as HRAS and MAPK1 hotspot mutations and potentially others, have remarkable tumoral ErbB3-suppression (first identified in TCGA data and validated in HNSCC tumors).